PFSA — Profusa, Inc.
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1859807 ·
Last close
$0.24
Market Cap
$1.10M
52W High
$2.25
52W Low
$0.22
ADV30
304,764
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -4,006,000 | -3,456,000 | 862,000 | 375,000 | 29,060,000 |
| Dec 2025 | 0 | — | -3,570,000 | -8,567,000 | 3,775,000 | 1,778,000 | 30,433,000 |
| Sep 2025 | 0 | — | -21,709,000 | -22,192,000 | 4,250,000 | 3,009,000 | 38,210,000 |
| Jun 2025 | 0 | — | -967,084 | -8,196,876 | 1,962,416 | 0 | 23,142,121 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-18,287,000
Investing CF
$-863,000
Financing CF
$19,506,000
CapEx
$-5,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-79.51
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-164,237,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-34,970,084
Pretax Income TTM
$-42,409,490
Interest Exp TTM
$1,347,000
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -27,706,000 | -35,823,000 | 3,775,000 | 30,433,000 | — | -16,248,000 |
| Dec 2024 | 0 | -4,500,000 | -9,230,000 | 3,073,000 | 122,278,000 | — | -2,066,000 |
| Dec 2023 | 0 | -6,070,000 | -10,281,000 | 1,893,000 | 111,889,000 | — | -4,402,000 |
| Dec 2022 | 0 | -9,443,000 | -20,217,000 | 1,031,000 | 100,802,000 | — | -7,702,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LYRA | Lyra Therapeutics, Inc. | $1.15M | $0.65 | — |
| LGMK | LogicMark, Inc. | $854.8K | $0.95 | — |
| NUMD | Nu-Med Plus, Inc. | $852.2K | $0.01 | — |
| YBGJ | Yubo International Biotech Ltd | $1.43M | $0.01 | — |
| ESMC | ESCALON MEDICAL CORP | $1.48M | $0.20 | — |
News headlines (Yahoo Finance, 1h cache)
Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform
2026-06-12 12:00 · Yahoo
Profusa Issues Letter to Shareholders Encouraging Shareholders to Vote FOR All Proposals at June 23, 2026 Annual Meeting
2026-06-10 12:00 · Yahoo
Profusa Announces Listing Transfer to The Nasdaq Capital Market
2026-05-15 11:30 · Yahoo
Profusa Receives Favorable Nasdaq Listing Determination
2026-05-08 10:00 · Yahoo
Profusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder Value
2026-05-05 12:30 · Yahoo
Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics Platform
2026-04-06 10:00 · Yahoo
Profusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering
2026-02-27 14:15 · Yahoo
Profusa Receives Purchase Orders for Lumee™ Tissue Oxygen Monitoring and Raises 2026 Revenue Guidance
2026-02-19 13:30 · Yahoo
Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies
2026-02-13 13:30 · Yahoo
Profusa Announces 1-for-75 Reverse Stock Split
2026-02-05 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.